Lipodermatosclerosis and Pulmonary Hypertension in Systemic Sclerosis
JAMA Dermatology · 2024
DOI: 10.1001/jamadermatol.2024.3929 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Srijana Davuluri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Rheumatology, Stanford School of Medicine, Palo Alto, California. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Scleroderma, Systemic. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Importance Lipodermatosclerosis (LDS) stems from vascular dysfunction and dermal inflammation and thereby is mechanistically similar to systemic sclerosis (SSc). The association of LDS with SSc in the clinical setting has not been well characterized in the literature.
Objective
To evaluate the prevalence of LDS in SSc and the association of LDS with vascular complications, particularly pulmonary hypertension, in patients with SSc. Design, Setting, and Participants This retrospective cohort study used prospectively collected longitudinal data from a cohort of patients from the multidisciplinary rheumatology and dermatology clinic at a single tertiary care center from November 2004 to November 2022. Adult patients (aged ≥18 years at the time of cohort entry) with SSc were included. Exposure Clinical diagnosis of LDS based on expert opinion or histopathologic findings. Main Outcomes and Measures The main outcomes included prevalence of LDS, the association of LDS with the macrovascular complications, including pulmonary hypertension, digital gangrene and/or scleroderma renal crisis. Disease complications, including cardiac arrhythmias and heart failure, were compared among patients with and without LDS.
Results
Among 567 patients with SSc (494 [87.1%] female; mean [SD] age, 53.4 [14.4] years), 25 (4.4%) had LDS and 542 (95.6%) did not have LDS. Skin ulceration occurred in 8 patients with LDS (32.0%). Patients with LDS had higher frequencies of cardiac arrhythmia (11 of 24 [45.8%] vs 145 of 539 [26.9%]), heart failure (7 [28.0%] vs 55 [10.1%]), and pulmonary hypertension (12 [48.0%] vs 137 of 541 [25.3%]) compared with patients without LDS. Frequency of scleroderma renal crisis and digital gangrene did not differ significantly between patients with and without LDS (0 vs 37 [6.8%] and 4 [16.0%] vs 69 of 538 [12.8%], respectively). Among patients with LDS, 9 (36.0%) were either discharged to hospice or died during follow-up compared with 115 patients without LDS (21.2%). Lipodermatosclerosis was associated with pulmonary hypertension (adjusted prevalence odds ratio, 3.10; 95% CI, 1.33-7.25). Conclusions and Relevance In this cohort study, LDS was a rare clinical manifestation in patients with SSc but was associated with pulmonary hypertension. Therefore, patients with LDS should be closely monitored and screened for pulmonary hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Immunology and Rheumatology, Stanford School of Medicine, Palo Alto, California.
- Division of Epidemiology and Population Health, Stanford University, Stanford, California.
- Department of Dermatology, Stanford School of Medicine, Stanford, California.
Förderung
- NIAMS NIH HHS
Zitieren
APA
Davuluri, S., Kapoor, P., Nandyala, S., Li, S., Simard, J., Lewis, M., Fiorentino, D., & Chung, L. (2024). Lipodermatosclerosis and Pulmonary Hypertension in Systemic Sclerosis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.3929
Vancouver
Davuluri S, Kapoor P, Nandyala S, Li S, Simard J, Lewis M, et al. Lipodermatosclerosis and Pulmonary Hypertension in Systemic Sclerosis. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.3929
BibTeX
@article{Davuluri2024,
author = {Davuluri, Srijana and Kapoor, Puneet and Nandyala, Swarna and Li, Shufeng and Simard, Julia and Lewis, Matthew and Fiorentino, David and Chung, Lorinda},
title = {Lipodermatosclerosis and Pulmonary Hypertension in Systemic Sclerosis},
journal = {JAMA Dermatology},
year = {2024},
doi = {10.1001/jamadermatol.2024.3929}
}
EUVIMED